Title:
【発明の名称】グルカゴンアンタゴニスト
Document Type and Number:
Japanese Patent JP2003531632
Kind Code:
A
Abstract:
The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
Inventors:
Marshall, William S
Stark, Kevin Lee
Stark, Kevin Lee
Application Number:
JP2001580951A
Publication Date:
October 28, 2003
Filing Date:
May 03, 2001
Export Citation:
Assignee:
Amjien Incorporated
International Classes:
C12N15/09; A61K38/00; A61K47/48; A61P3/10; A61P5/00; A61P43/00; C07K1/107; C07K14/605; C07K16/00; C12N1/21; C12P21/02; C12R1/19; (IPC1-7): C12N15/09; A61K38/00; A61K47/48; A61P3/10; A61P5/00; A61P43/00; C07K1/107; C07K14/605; C07K16/00; C12N1/21; C12P21/02
Attorney, Agent or Firm:
Yoshio Kawaguchi (4 outside)